ロード中...
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
In recent years, several nonhormonal and hormonal agents, including enzalutamide, have been approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) on the basis of improved overall survival in prospective clinical trials. The incorporation of these agents has revolutioni...
保存先:
| 出版年: | Drug Des Devel Ther |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4492664/ https://ncbi.nlm.nih.gov/pubmed/26170619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S69433 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|